Baillie Gifford & Co. Has $743.02 Million Position in BioNTech SE Sponsored ADR (NASDAQ:BNTX)

Key Points

• Baillie Gifford & Co. has reduced its stake in BioNTech by 0.7%, owning approximately 3.40% of the company's shares, valued at $743 million after selling 60,899 shares.
• A number of other institutional investors, including the Bank of New York Mellon Corp and Probity Advisors Inc., have also increased their holdings in BioNTech during the recent quarters.
• BioNTech's current stock rating is a "Moderate Buy" with an average price target of $136.58, according to 19 investment analysts.

Baillie Gifford & Co. lessened its stake in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 0.7% in the first quarter, according to its most recent filing with the SEC. The fund owned 8,159,682 shares of the company's stock after selling 60,899 shares during the period. Baillie Gifford & Co. owned about 3.40% of BioNTech worth $743,021,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Allianz SE purchased a new stake in shares of BioNTech in the fourth quarter valued at $90,000. Goodman Advisory Group LLC purchased a new stake in shares of BioNTech in the first quarter valued at $105,000. Tower Research Capital LLC TRC lifted its holdings in shares of BioNTech by 61.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,881 shares of the company's stock valued at $214,000 after purchasing an additional 713 shares in the last quarter. Probity Advisors Inc. lifted its holdings in shares of BioNTech by 8.5% in the fourth quarter. Probity Advisors Inc. now owns 1,970 shares of the company's stock valued at $224,000 after purchasing an additional 154 shares in the last quarter. Finally, Whittier Trust Co. lifted its holdings in shares of BioNTech by 3,846.2% in the first quarter. Whittier Trust Co. now owns 2,052 shares of the company's stock valued at $187,000 after purchasing an additional 2,000 shares in the last quarter. Institutional investors and hedge funds own 15.52% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. Wall Street Zen upgraded BioNTech from a "sell" rating to a "hold" rating in a report on Saturday, June 7th. JPMorgan Chase & Co. reduced their target price on BioNTech from $120.00 to $116.00 and set a "neutral" rating for the company in a report on Thursday, May 22nd. Truist Financial restated a "buy" rating and issued a $155.00 target price (up previously from $151.00) on shares of BioNTech in a report on Tuesday, June 3rd. Morgan Stanley increased their price objective on BioNTech from $132.00 to $133.00 and gave the stock an "overweight" rating in a report on Thursday, July 10th. Finally, Bank of America cut their price objective on BioNTech from $127.00 to $126.00 and set a "buy" rating for the company in a report on Wednesday, July 16th. Five equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $136.58.

BioNTech Stock Down 1.5%

BioNTech stock traded down $1.74 during mid-day trading on Tuesday, hitting $111.05. 414,490 shares of the company's stock were exchanged, compared to its average volume of 953,287. The company has a current ratio of 10.18, a quick ratio of 10.02 and a debt-to-equity ratio of 0.01. The stock has a market cap of $26.70 billion, a P/E ratio of -32.63 and a beta of 1.29. BioNTech SE Sponsored ADR has a 1-year low of $76.53 and a 1-year high of $131.49. The stock has a 50 day moving average of $107.35 and a two-hundred day moving average of $106.29.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.